Clinical Trial Update: Apatinib Combined With PD-1 in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma [Phase 2]

View source ↗

Summary

A phase 2 clinical trial evaluating apatinib in combination with PD-1 inhibitor for recurrent or metastatic nasopharyngeal carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• Apatinib (apatinib)

Snippet

Sponsor: Wei Jiang | Conditions: Nasopharyngeal Carcinoma | Phase 2 | Status: COMPLETED